Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex generics.
Cipla bets on fast-growing biosimilars market, to steadily add products: CEO
